drugset / Trial / NCT00488826

Study Evaluating 7-Valent Pneumococcal Conjugate Vaccine in Healthy Infants

NCT00488826

Phase 1 Completed 800 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupOpen-labelPrevention

Summary

This study is a combination of a Phase I and Phase III study design. The Phase I portion is an open-label, controlled study to evaluate the safety of 7vPnC in healthy Chinese infants. The Phase III portion is an open-label, controlled, randomized study to evaluate the safety and immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine (7vPnC)in healthy Chinese infants. Both phases include a Primary Series which includes the primary 3 doses of 7vPnC and /or Diptheria and tetanus toxoids and accelular pertussis vaccine (DTaP) at about 3, 4, and 5 months of age; and a Booster Dose which includes the 4th dose of 7vPnC at 12-15 months of age.

Timeline

Start
2005-10
Primary completion
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Diptheria and tetanus toxoids and accelular pertussis vaccine Vaccine
Subject Prevnar 13 Vaccine